Capasso Planning Partners LLC Boosts Holdings in AbbVie Inc. $ABBV

Capasso Planning Partners LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 97.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,979 shares of the company’s stock after purchasing an additional 2,459 shares during the period. AbbVie comprises 0.6% of Capasso Planning Partners LLC’s portfolio, making the stock its 25th largest position. Capasso Planning Partners LLC’s holdings in AbbVie were worth $1,083,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie in the fourth quarter worth about $28,000. Imprint Wealth LLC increased its holdings in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID raised its position in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie in the 4th quarter valued at approximately $31,000. Finally, WestEnd Advisors LLC boosted its stake in shares of AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Royal Bank Of Canada upped their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Canaccord Genuity Group boosted their target price on shares of AbbVie from $273.00 to $282.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Cantor Fitzgerald upped their target price on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, July 6th. HSBC reaffirmed a “buy” rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Finally, Guggenheim boosted their price objective on AbbVie from $249.00 to $261.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

AbbVie Stock Down 2.4%

Shares of NYSE ABBV opened at $251.33 on Friday. The stock has a market cap of $444.05 billion, a P/E ratio of 123.81, a P/E/G ratio of 0.85 and a beta of 0.30. The firm’s 50-day simple moving average is $239.10 and its 200 day simple moving average is $224.05. AbbVie Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $267.47.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.78 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.14 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.